Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972253 | 0.86 | CDK8 (0.52) | CDK8 | |
| SCHEMBL11972382 | 0.85 | AKR1C3 (0.61) | CDK8 | |
| SCHEMBL2734773 | 0.84 | CDK8 (0.53) | CDK8 | |
| SCHEMBL4744314 | 0.84 | CYP11B1 (0.49) | CDK8 | |
| SCHEMBL20616269 | 0.84 | L3MBTL1 (0.52) | CDK8L3MBTL1 | |
| SCHEMBL2436534 | 0.82 | L3MBTL1 (0.65) | L3MBTL1 | |
| SCHEMBL5873911 | 0.81 | SMN1; SMN2 (0.58) | L3MBTL1 | |
| SCHEMBL11997727 | 0.81 | CDK8 (0.59) | CDK8 | |
| SCHEMBL2060395 | 0.81 | L3MBTL1 (0.49) | L3MBTL1 | |
| SCHEMBL25910847 | 0.81 | MRGPRX4 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| EP-2081928-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008060907-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | IGF1R, FGFR1, FLT1 | CDK8 474/4885L3MBTL1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.